Adenoid Cystic Carcinoma Market

Market Overview:

The 7 major adenoid cystic carcinoma markets reached a value of US$ 164.0 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 260.7 Million by 2034, exhibiting a growth rate (CAGR) of 4.3% during 2024-2034.

The adenoid cystic carcinoma market has been comprehensively analyzed in IMARC's new report titled "Adenoid Cystic Carcinoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Adenoid cystic carcinoma (ACC) refers to a rare and slow-growing malignant tumor that primarily originates in the salivary glands. However, it can also occur in other locations like the breast, trachea, and lacrimal glands. This disease is characterized by its unique growth pattern, forming glandular and cyst-like structures surrounded by dense fibrous tissue. The symptoms of ACC vary depending on the affected area but commonly include pain, swelling, and discomfort. In salivary gland cases, individuals suffering from the ailment might experience difficulty in swallowing, changes in speech, facial paralysis, or a lump in the neck or mouth. The diagnosis of ACC typically involves a combination of imaging studies, such as ultrasounds, magnetic resonance imaging, computed tomography scans, etc. In addition to this, a biopsy is performed to confirm the presence of malignant cells. Pathological examination of the tissue is crucial for accurate diagnosis, as ACC can resemble other benign or malignant growths.

The escalating incidences of somatic mutations, leading to the abnormal growth of glandular and epithelial cells, chiefly in the salivary glands and various other glandular structures, are primarily driving the adenoid cystic carcinoma market. In addition to this, the inflating utilization of precision medicine approaches, which involve tailoring treatments based on genetic profiles and molecular characteristics of tumors, is also creating a positive outlook for the market. Moreover, the widespread adoption of targeted therapeutics, such as tyrosine kinase inhibitors, immune checkpoint inhibitors, anti-angiogenic drugs, etc., for managing, preventing, and containing ACC is further bolstering the market growth. Apart from this, the rising usage of multidisciplinary approaches, integrating surgery and systemic treatments, on account of their various advantages, like enhanced patient outcomes, reduced risk of recurrence, maximized therapeutic benefits, etc., is acting as another significant growth-inducing factor. Additionally, the emerging popularity of radiation therapy, since it utilizes high-energy rays to kill or reduce cancer cells, is also augmenting the market growth. Furthermore, the increasing demand for novel diagnostic techniques such as liquid biopsies, which involve collecting and analyzing circulating tumor DNA or other genetic material in bodily fluids, thereby standing poised to revolutionize early detection and monitoring, is expected to drive the adenoid cystic carcinoma market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the adenoid cystic carcinoma market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for adenoid cystic carcinoma and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the adenoid cystic carcinoma market in any manner.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the adenoid cystic carcinoma market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the adenoid cystic carcinoma market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current adenoid cystic carcinoma marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the adenoid cystic carcinoma market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the adenoid cystic carcinoma market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the adenoid cystic carcinoma market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of adenoid cystic carcinoma across the seven major markets?
• What is the number of prevalent cases (2018-2034) of adenoid cystic carcinoma by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of adenoid cystic carcinoma by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with adenoid cystic carcinoma across the seven major markets?
• What is the size of the adenoid cystic carcinoma patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of adenoid cystic carcinoma?
• What will be the growth rate of patients across the seven major markets?
   

Adenoid Cystic Carcinoma: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for adenoid cystic carcinoma drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the adenoid cystic carcinoma market?
• What are the key regulatory events related to the adenoid cystic carcinoma market?
• What is the structure of clinical trial landscape by status related to the adenoid cystic carcinoma market?
• What is the structure of clinical trial landscape by phase related to the adenoid cystic carcinoma market?
• What is the structure of clinical trial landscape by route of administration related to the adenoid cystic carcinoma market?